Eli Lilly expands self-pay access to Zepbound KwikPen through LillyDirect and major U.S. pharmacies, with prices starting at $299 per month for the 2.5 mg starting dose.
Written By: Pharmacally Medical News Desk
Eli Lilly and Company has expanded pharmacy access to Zepbound (tirzepatide) KwikPen, allowing patients enrolled in the company’s self-pay program to obtain the medication through major U.S. retail pharmacies as well as the LillyDirect platform.
Although the company announcement states availability “beginning now,” the Zepbound KwikPen self-pay program initially launched in late February 2026 through LillyDirect. The latest update extends the same pricing access to patients filling prescriptions at participating pharmacies nationwide through a newly introduced KwikPen Self-Pay Savings Card.
Under the program, pricing varies by dose. The 2.5 mg starting dose is available from $299 per month, while higher doses are priced at higher tiers through LillyDirect. The 5 mg dose is available for approximately $399 per month, and higher doses may reach about $449 per month, depending on the prescribed strength.
Adults with a valid on-label prescription for Zepbound KwikPen can use the savings card to obtain the same self-pay pricing whether they choose to pick up their medication at a local pharmacy or receive home delivery through LillyDirect. The savings program applies only to the KwikPen presentation and does not apply to single-dose vials or the single-dose pen.
Zepbound is an injectable prescription medicine indicated for chronic weight management in adults with obesity or adults with overweight who also have weight-related medical conditions. The therapy has also been approved to improve moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Treatment should be used alongside a reduced-calorie diet and increased physical activity.
The medicine is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths administered once weekly by subcutaneous injection. The 2.5 mg dose is intended as a starting dose, while recommended maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg weekly, and 10 mg or 15 mg weekly for obstructive sleep apnea.
Zepbound contains tirzepatide and should not be used with other tirzepatide-containing medicines or with GLP-1 receptor agonists. The safety and effectiveness of the therapy in pediatric patients have not been established.
For complete prescribing details, including boxed warnings, contraindications, precautions, and adverse reactions, refer to the official Zepbound Prescribing Information (USPI).
Reference
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect, 16 March 2026, Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect | Eli Lilly and Company